A Phase I trial of AR1003 for Sepsis.

Trial Profile

A Phase I trial of AR1003 for Sepsis.

Phase of Trial: Phase I

Latest Information Update: 20 Oct 2016

At a glance

  • Drugs AR 1003 (Primary)
  • Indications Sepsis
  • Focus Adverse reactions
  • Most Recent Events

    • 20 Oct 2016 New trial record
    • 01 Jun 2016 According to an AriBio media release, this trial will be conducted in 2017 after granting FDA IND license.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top